Qube Research & Technologies LTD Athira Pharma, Inc. Transaction History
Qube Research & Technologies LTD
- $65.7 Billion
- Q3 2024
A detailed history of Qube Research & Technologies LTD transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 63,033 shares of ATHA stock, worth $37,189. This represents 0.0% of its overall portfolio holdings.
Number of Shares
63,033Holding current value
$37,189% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding ATHA
# of Institutions
66Shares Held
16.9MCall Options Held
112KPut Options Held
68K-
Perceptive Advisors LLC New York, NY5.4MShares$3.19 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.61MShares$951,7070.0% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$880,7470.04% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$880,7470.39% of portfolio
-
Black Rock Inc. New York, NY676KShares$398,9830.0% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $22.3M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...